Riskpilot← Back to searchSign inGet full accessGunneflo Life Science AB
ABActiveOrg 5566879622Jan Inghes Torg 30Business and other management consultancy activities · NACE 7020Est. 20050 employees
Revenue 2025
SEK 0
EBITDA margin
—
-112% vs 2024
Equity ratio
99.5%
Financial strength
Net profit 2025
SEK -169K
-158% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -15K | -112% |
| Net profit | SEK -169K | -158% |
| Total assets | SEK 3,3M | -12% |
| Equity | SEK 3,3M | -10% |
| Employees | 0 | — |
Legal name
Gunneflo Life Science AB
Org number
5566879622
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
17 oktober 2005
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva konsultation inom medicin och management riktad mot privat och offentlig sektor. Bolaget skall bedriva import, distribution samt försäljning av läke- och hälsomedel samt marknadsföring av sådana produkter.
Address
Jan Inghes Torg 30
Phone
+4686421294
Email
lars@gunneflo.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 32 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −15 | −47 | −37 | −7 | −15 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | −15 | −47 | −37 | −7 | −15 |
| Net financials | 51 | 1 | −71 | 294 | −164 |
| Profit before tax | 35 | 5 | 229 | 293 | −169 |
| Tax | −0 | −0 | −59 | — | — |
| Net profit | 35 | 5 | 170 | 293 | −169 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 174 | 3 936 | 3 650 | 3 733 | 3 286 |
| Equity | 3 777 | 3 587 | 3 561 | 3 650 | 3 271 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 15 | 18 | 59 | 59 | 0 |
| Total debt | 15 | 18 | 59 | 59 | — |
EBITDA margin
-1455600.0%
This company
15.8%
Market median
-9212758% vs market
20212025
Equity ratio
99.5%
This company
38.2%
Market median
+160% vs market
20212025
Return on equity
-5.2%
This company
18.4%
Market median
-128% vs market
20212025
Net profit margin
-16910600.0%
This company
8.1%
Market median
-208772940% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
MG | Audit | 2022 |
LG Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Gunneflo Life Science AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| My Gudrun Maria Bolin | Audit | 0 companies |
| Lars Gustaf Gunneflo | Chief Executive Officer | 0 companies |
| Birgitta Fernström Gunneflo | Deputy Board Member | 0 companies |